Qiagen, Ventana settle dispute
This article was originally published in The Gray Sheet
Executive Summary
Qiagen (formerly Digene) and Ventana Medical settle their dispute over patents related to human papillomavirus tests Dec. 15. Ventana will pay an undisclosed cash amount. Qiagen is involved in ongoing disputes with other HPV test developers Third Wave Technologies and Roche (1"The Gray Sheet" Oct. 22, 2007, p. 22)
You may also be interested in...
Digene Fights Antitrust Charges As Part Of HPV Diagnostics Patent Case
Human papillomavirus test maker Digene, recently acquired by Qiagen, is defending itself against allegations of anti-competitive business practices from Third Wave Technologies as part of a larger patent battle between the firms
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.